Abstract Tamoxifen-an anti-estrogenic ligand in breast tissues used as a first-line treatment in estrogen receptor (ER)-positive breast cancers-is associated with the development of resistance followed by resumption of tumor growth in about 30 % of cases. Whether tamoxifen assists in proliferation in such cases or whether any ligand-independent pathway to transcription exists is not fully understood; also, no ERα mutants have been detected so far that could lead to tamoxifen resistance. Using in silico conformational analysis of the ERα ligand binding domain (LBD), in the absence and presence of selective agonist (diethylstilbestrol; DES), antagonist (Faslodex; ICI), and selective estrogen receptor modulator (SERM; 4-hydroxy tamoxifen; 4-OHT) ligands, we have elucidated ligand-responsive structural modulations of the ERα-LBD dimer in its agonist and antagonist complexes to address the issue of "tamoxifen resistance". DES and ICI were found to stabilize the dimer in their agonist and antagonist conformations, respectively. The ERα-LBD dimer without the presence of any bound ligand also led to a stable structure in agonist conformation. However, binding of 4-OHT to the antagonist structure led to a flexible conformation allowing the protein to visit conformations populated by agonists as was evident from principal component analysis and radius of gyration plots. Further, the relaxed conformations of the 4-OHT bound protein exhibited a diminished size of the co-repressor binding pocket in the LBD, thus signaling a partial blockage of the co-repressor binding motif. Thus, the ability of 4-OHT-bound ERα-LBD to assume flexible conformations visited by agonists and reduced co-repressor binding surface at the LBD provide crucial structural insights into tamoxifen-resistance that complement our existing understanding.
Introduction
Breast cancer, accounting for more than 458,500 deaths worldwide every year, is still one of the primary malignancies in women [1] . Among several key molecular pathways, the most important one involves estrogen receptor alpha (ERα) [2] [3] [4] as about 70 % of breast tumors are ERα-positive and depend on estrogenic ligand for progression of the tumor. ERα, a member of the nuclear hormone receptor family, is a ligand-based transcription factor [5, 6] that controls the expression of hundreds of genes responsible for diverse phenotypic properties like growth, motility, and differentiation [7, 8] . Among five major domains of ERα, the ligand binding domain (LBD) is considered to be the key structural domain that controls liganddependent regulation of ER signaling through N-and C-terminal activation function domains (AF-1 and AF-2) and, as such, has been the focus of intense structural studies.
Binding of estrogenic ligands (agonist) to ERα LBD leads to conformational changes suitable for dimerization, recruitment of co-activator proteins and binding to the DNA estrogen response element (ERE) in the promoter region of target genes [9] [10] [11] . Similar to agonist ligands, antagonist (antiestrogenic) ligands also induce conformational changes on ERα. However, ERα conformations that result from the binding of an antiestrogenic ligand are quite different from those arising from the binding of an agonist ligand. The former is expected to prevent the binding of co-activator signal-transmitting proteins, thus, acting as an antagonist, impairing hormone-dependent ER transactivation [12] . Comparison of agonist and antagonist ligand bound ERα-LBD crystal structures (3ERD.pdb and 3ERT.pdb) revealed that Helix 12 plays a critical role in agonism or antagonism. The bulky sidechain of selective estrogen receptor modulator (SERM) 4-hydroxy tamoxifen (4-OHT) provokes steric clashes with Helix 12 forcing it to adopt its characteristic antagonist conformation where it orients in the co-activator recognition groove in ERα-LBD. It is to be noted that Helix 12 itself possesses a LXXLL sequence motif that perfectly mimics the interactions with co-activator peptides, thus allowing blockage of the co-activator binding [13] .
Among several classes of anti-estrogenic ligand, ICI 182,780 (Faslodex) acts as a complete antagonist in all tissues [14] . On the other hand, 4-OHT is better classified as a SERM, which behaves as ER antagonists in breast tissues only [15, 16] . About 30 % of ER-positive breast cancers that initially respond well to tamoxifen (a SERM) by cessation of growth or regression, eventually resume growth despite the continued presence of the SERM and most tamoxifenresistant tumors continue to express ER [17, 18] . Recent studies have elucidated some of the molecular reasons that link in vitro models of tamoxifen's estrogenic effects with clinical reports of tamoxifen resistance, which is thought to originate from the various aspects of estrogen signalling, interactions with co-regulators, and the interplay with growth factor signalling pathways [19] [20] [21] [22] [23] . Studies on mouse models have demonstrated that, by blocking co-repressor NCoR activity, 4-OHT behaved like an agonist [24] . Thus, both co-repressor expression and binding ability to the protein could be deciding factors in tamoxifen resistance. However, the definitive molecular mechanism of tamoxifen resistance remains unknown. To the best of our knowledge, no structural details are available on how both the agonist and antagonist conformations of ERα are accessible in the presence of tamoxifen.
Here, we present structural insights into the effect of selective ligand responses on the ERα transactivation pathway; we carried out four different molecular dynamics (MD) simulations of the ERα-LBD dimer in which each pair of monomers is bound with two ligands: (1) agonist (diethylstilbestrol, DES), (2) SERM (4-hydroxy tamoxifen, 4-OHT), and (3) pure antagonist (ICI 182,780, ICI). We also considered the ERα-LBD dimer without any bound ligand. Our results show the distinctive behavior of ERα-LBD dimer conformational dynamics, which is dependent on the bound ligand subtype. Interestingly, ERα-LBD can form a stable dimer without binding to any ligand as well as in the presence of bound agonist and antagonist/SERM. DES and ICI stabilize the agonist and antagonist conformation of the ERα-LBD dimer in terms of Helix 12 position. The presence of bound 4-OHT in the LBD changes the conformational dynamics of the ERα-LBD dimer in such a way that both the agonist and antagonist conformations are accessible. Through in silico simulation, we found that the antagonist conformation of the ERα-LBD 4-OHT complex does allow the binding of co-repressor(s) while the agonist conformation obtained from MD simulations of tamoxifen-bound ERa-LBD does not allow the binding of co-repressors, since the co-repressor binding pocket is diminished. Thus, a decreased expression of co-repressor protein and/or a diminished co-repressor binding pocket might allow ERα to switch from antagonist to agonist conformation and lead to the observed tamoxifen-induced ERα transactivation [24] .
Materials and methods

Modeling of the ERα homo-dimer in agonist and antagonist conformations
The crystal structure of the ERα LBD homo-dimer (PDB ID: 3ERD) where each monomer is bound with the agonist ligand DES was considered as ERα LBD dimer agonist conformation. Each monomer comprises residues 305-550, and Helix 12 is positioned properly to accommodate co-activator proteins. There are some key residues missing (residues 462-469) in chain B at the dimer interface connecting Helix 8 to Helix 9 in the crystal structure (PDB ID: 3ERD). All the missing residues were modelled using MODELLER 9.9 [25] . The missing sequence was also modelled by superimposing chain B on chain A followed by manual grafting of the missing residues from chain A to chain B using VMD [26] . Both modelled structures were then energy minimized using GROMACS [27, 28] MD code with OPLS [29] force field, and their stereo-chemical quality was checked PROCHECK as implemented on the SAVES web server (http://nihserver. mbi.ucla.edu/SAVES_3). Both the agonist and antagonist dimers appear to be of very high quality; there were no residues in the disallowed region of the Ramachandran plot and 100 % of residues fall within the core and extended allowed region. Finally, the crystal structure with manual grafting of missing residues in chain B was used in our study as it exhibited greater symmetry of monomers in the dimer structure.
A ligand-free ERα LBD dimer was prepared from the modelled ERα LBD dimer structure by removing the bound DES from each monomer and then relaxing the resulting structure through energy minimization and equilibration at 300 K in the presence of explicit water. It should be noted that the ligandfree ERα LBD dimer was modelled in agonist conformation in terms of Helix 12 orientation. On the other hand, for the ERα LBD dimer bound with a SERM, we used the crystal structure of ERα LBD (PDB ID 3ERT) where the SERM 4-OHT is bound to the LBD and Helix 12 positioned itself in such a way as to prevent co-activator binding. This LBD was used to prepare the ERα LBD dimer in antagonist conformation using a homology modelling procedure available in the SWISS-MODEL [30] web-interface with 3ERT as a template structure.
To prepare an ERα LBD dimer bound with pure antagonist ICI 182,780 (referred as ICI throughout the text), the 3ERT crystal structure for ERα LBD was used to dock ICI using AutoDock 4.2 [31] . All hetero atoms were deleted and nonpolar hydrogens were merged as required by AutoDock. The Kollman united-atom charge model was applied to the protein.
Atomic solvation parameters and fragmental volumes were added to the protein. Grid maps were generated using the empirical free-energy scoring functions in AutoDock. A grid box of 120×120×120 grid points with a grid-point spacing of 0.375 Å was considered for docking. The box was centered such that it covers the entire LBD. The three-dimensional (3D) co-ordinates of the ligand (ICI) were obtained from the PubChem compound library (CID 104741). Rotatable bonds were assigned and non-polar hydrogens were merged. Partial atomic charges were calculated using the Gasteiger-Marsili method for the ligand. A total of 250 docking runs was performed and for each run, a maximum of 2,500,000 GA operations were carried out on a single population of 150 individuals. The weights for crossover, mutation, and elitism were default parameters of 0.8, 0.02 and 1, respectively. The lowest energy docked complex of ERα LBD monomer and ICI was selected to build the dimer based on the ERα LBD dimer bound with 4-OHT (described in the previous section) as a template. This lowest energy docked complex was then solvated and equilibrated in the presence of explicit water to prepare the system to run MD. A schematic representation of all three ligands considered in this study is shown in Scheme 1.
Molecular dynamics simulation
The parameters for DES, 4-OHT, and ICI were developed according to OPLS force-field defined atomic groups. The atomic partial charges were readjusted to maintain the charge neutrality of the whole molecule. The parameters were tested by comparing the GROMACS energy minimized structures with the respective crystal structures and similar energy minimized structures obtained using CPMD [32] .
Each ERα LBD dimer complex (with or without a ligand) was subjected to a preliminary short energy minimization in vacuo using the steepest descent algorithm. The system was then solvated with the explicit water model in a cubic box with periodic boundary conditions; the box dimensions were chosen such that all the protein atoms were at a distance equal to or greater than 1 nm from the box edges. The ionization state of residues was set to be consistent with neutral pH and 12 Na+ions were added to make the system neutral. The solvated system was then subjected to a second short energy minimization of 500 steps using the steepest descent algorithm to eliminate any bad contacts with water. After that, a 200-ps position restrained dynamics was carried out whereby the complex was restrained by restraining forces while the water molecules were allowed to move. This was then followed by a 500-ps NVT simulation at 300 K and a 500-ps NPT simulation to achieve suitable equilibration of the system to be simulated. Final production simulations were performed in the isothermalisobaric (NPT) ensemble at 300 K, using an external bath with a coupling constant of 0.1 ps. The pressure was kept constant (1 bar) by using pressure coupling with the time-constant set to 1 ps. The LINCS [33] algorithm was used to constrain the bond lengths, allowing the use of a 2.0-fs time step. Van der Waals and Coulomb interactions were truncated at 1.4 nm and the GROMACS implemented SHIFT function was used to reduce truncation error. MD trajectories were stored every 5 ps.
Structural analyses were carried out using the in-built tools of GROMACS and secondary structure assignments were carried out with the DSSP [34] module integrated with GROMACS. The RMSD matrices were computed on each of the trajectories by the least square fitting of main-chain atoms, and the matrices were then processed to extract clusters of similar conformations.
Principal component analysis
Principal component analysis was performed on each of the ligand bound ERα-LBD dimer trajectories obtained from the MD simulations in order to obtain an insight into the essential dynamics of the simulated system in reduced sub-space. Mass-weighted covariance matrix of atomic positional fluctuations was calculated from each MD trajectory fitted on Cα atoms of the reference structure and analyses were performed on backbone atoms. The essential subspace was then defined in terms of the calculated eigenvectors.
Identification of hotspot residues at the dimer interface
The essential protein-protein interface interaction of the homo-dimer was explored using the HotPoint online webserver [35] for the four MD average structures of ERα-LBD dimer (one without ligand, and three in the presence of DES, 4-OHT and ICI, respectively) obtained from covariance analysis. The server also predicts hotspot residues involved in crucial interactions for the dimer interface.
Binding pocket and co-repressor binding analysis
The initial and the final average structures of 4-OHT-bound ERα-dimer obtained from the MD simulation were analyzed further to identify putative binding pockets using the QSiteFinder [36] program. Investigation of co-repressor peptide docking at the identified binding site was carried out using RosettaDock [37] web-interfaces.
Results
In order to gain an insight into the stability and structural dynamics of the ERα-LBD dimer and its dependency on the bound ligand subtypes, MD simulations were performed on both ligand-bound and ligand-free ERα-LBD homo-dimer. Stability of the agonist and antagonist ERα-LBD dimer conformations with respect to bound ligand subtypes was explored using root mean square deviation (RMSD), radius of gyration (R g ), and cluster analysis. We also investigated changes in secondary structure in the essential dimer interfaces induced by the bound ligand. A comparison of the essential dynamics of ERα dimer bound with various ligand sub-types (agonist, antagonist and SERM) was carried out using principal component analysis (PCA). In addition, in silico studies were carried out to explore prototype co-repressor peptide interactions with ERα-LBD in order to understand the probable mechanisms of tamoxifen resistance. Detailed results are given below.
Stability of ERα dimer and its dependency on bound ligand Figure 1 presents the variation of dynamic parameters RMSD and R g of the ERα-LBD dimer in the absence and presence of three ligands (4-OHT, DES, and ICI) as a function of time.
As evident from Fig. 1a , during the first 2 ns of the simulation, all four different systems underwent conformational readjustments according to their respective ligands and environments and monotonically reached an equilibrium state. A closer look at each trajectory obtained from the MD simulation reveals that ERα-LBD dimers remained stable overall throughout the simulation regardless of the presence or absence of any ligand. ERα-LBD dimers do not dissociate in the presence of a bound SERM or pure antagonist, and remain stable throughout the simulation period. Also, interestingly, we found that ERα-LBD itself has the ability to form a stable dimer without any bound ligand. Binding of an agonist ligand, DES, in the LBD, stabilizes the dimer with an average RMSD value of 0.16±0.02 nm for an initial 7 ns and, in the last 3 ns of simulation of DES bound ERα dimer, the RMSD increases and stabilizes to a higher value 0.27± 0.17 nm. In comparison, the ligand free ERα-LBD dimer, the average RMSD is 0.21±0.03 nm. It is noteworthy that binding of a SERM to the LBD induces perturbation in the dimer complex but that does not lead to any dissociation of the complex. The average RMSD of the ERα-dimer when 4-OHT is bound to the LBD is 0.28±0.06 nm. It should be mentioned that the binding of ICI to the LBD stabilizes the dimer complex further but in an antagonist conformation, with an average RMSD of 0.21±0.03 nm over the same simulation period. The observed high fluctuations in the RMSD profile in the case of 4-OHT bound ERα-LBD dimer signify some structural transition in the dimer complex. We gained further insight into structural changes by analysing R g . R g defines the overall shape and dimensions of the protein. The plot of variation of R g of each LBD dimer with time is shown in Fig. 1b . It can be seen that, for unliganded and DES-bound ERα dimer, the starting conformation for MD simulation is in agonist conformation, while in the case of 4-OHT and ICI bound ERα dimer, it is in antagonist conformation. Due to the orientational difference of Helix 12, the antagonist/SERM bound ERα dimer has a higher R g compared to free or DESbound ERα-LBD dimer. Again, it is evident from Fig. 1b that the binding of DES stabilizes the LBD dimer in agonist conformation as seen from the R g profile, which is more stable compared to the unliganded ERα dimer R g profile throughout the course of the simulation. Binding of a pure antagonist, ICI, also stabilizes the LBD dimer but in an antagonist conformation, as evident from the stable R g profile throughout the simulation time. On the contrary, binding of a SERM or 4-OHT displays a distinctive feature in the R g profile. During the initial phase of the simulation, 4-OHT bound ERα-LBD dimer appears in antagonist conformation and its R g value is comparable to that of ICI bound ERα-LBD dimer. However, with simulation over time, its R g value decreases and converges with the R g value of the agonist (DES) bound ERα dimer signifying a structural transition from an antagonist to an agonist conformation.
Cluster analysis
To provide a detailed insight into all the onformations of the ERα dimer visited during MD simulation, RMSD matrices were computed and the results are displayed in Fig. 2 . In the absence of any ligand, the ERα-LBD dimer is quite stable throughout the simulation period. A single population of the dimer conformation is observed during the simulation, which is structurally very close to the initial agonist conformation in terms of Helix 12 orientation (Fig. 2a) . Binding of an estrogenic ligand, DES, also stabilizes the agonist conformation. Throughout the MD simulation, the initial agonist conformation is highly populated and structurally distinct conformational clusters are visited very less frequently (Fig. 2b) . The RMSD matrix profile is distinctively different when 4-OHT, a SERM, is bound in the LBD. It should be noted that the initial structure of ERα-LBD dimer in the MD simulation is in antagonist conformation. Throughout the simulation period, this initial antagonist conformation is much less populated and structurally distinct conformations are more frequently visited. In fact, in the R g plot (Fig. 1b) , we observed that, when 4-OHT is bound in the LBD, with time the ERα-LBD dimer shifts from an antagonist to an agonist conformation. So, the distinct conformational subspace is shape wise very close to the agonist conformation, while for the pure antagonist ICI, the starting structure of ERα-LBD dimer for MD simulation is in antagonist conformation with respect to Helix 12 orientation and throughout the simulation period this antagonist conformation is highly populated. This signifies that the binding of pure antagonist, ICI, shifts the agonist-antagonist conformational equilibrium towards the antagonist structure.
Effect of bound ligand sub-types on the essential ERα dimer interface
We further studied the effect of bound ligand sub-type on the dimer interface of ERα-LBD dimer. The essential dimer interface was characterized from changes in the solvent accessible surface area (SASA) of the monomer and dimerized ERα-LBD. Upon dimerization, those residues that undergo a reduction in the SASA value>20 Å 2 , were considered to be involved in the dimer interface. As evident from Fig. 3 , four regions mainly contribute to the dimer interface. Residues 421-437 of Helix 7 are defined as region I (red), residues 448-461 from the C-terminal portion of Helix 8 as region II (orange), residues 473-490 from Helix 9 (magenta) as region III and residues 473-490 from Helix 10 and N-terminal portion of Helix 11 (blue) as region IV. In addition, we also consider Helix 12 (cyan) to define region V. It is worth noting that, in DES bound ERα-LBD dimer, Helix 12 orients towards the dimer interface, but in the 4-OHT or ICI bound ERα-LBD dimer, Helix 12 orients away from the dimer interface, thus losing its contribution to the essential dimer interface.
We next analyzed the effect of bound ligand on the secondary structure of each region of the dimer interface. Regions I, II and III adopt a stable α-helical structure and the binding of any agonist/antagonist ligand does not induce any perturbation in the secondary structural profile of these regions (data not shown). Region IV, on the other hand, was involved in crucial interactions in dimer interface and underwent significant changes in its secondary structure upon ligand binding, as shown in Fig. 4a .
An interesting observation is that, in the absence of a bound ligand, Helix 10 and 11 appear as a continuous helix. It is worth mentioning that in other nuclear receptor family proteins, helix 10 and 11 are separated by a kink or bend. As evident from the Fig. 4a (II) , the binding of an estrogenic ligand, DES, induces the propensity for a strong turn between Helix 10 and 11 and separates the two helices (indicate by the yellow line in the middle of this region). In the presence of 4-OHT (SERM), the turn propensity of the region between helix 10 and 11 reduces further. Interestingly in the last 4 ns of the simulation period, the turn propensity increases compared to the initial 3 ns. On the contrary, when ICI, a pure antagonist, is bound to the LBD, the turn propensity of the intermediate region between helix 10 and 11 diminishes and the two helices appear as a continuous helix. This observation plays an important role in co-repressor protein recognition (as discussed further below). Figure 4b displays the variation in the secondary structural profile of Helix 12 with simulation time. In the absence of any ligand or in the presence of bound DES, this region adopts an α-helical structure throughout the simulation time. However, the secondary structural profile undergoes a significant distortion in the presence of 4-OHT. During the simulation, Helix 12 appears mostly as a helical turn. MD simulation reveals that the binding of ICI in the LBD completely disrupts the secondary structure of this region; it appears as highly flexible bend/coil like conformation.
Interaction energy and "hotspot" residue analysis Table 1 summarizes the interaction energies between each of the four regions with the other monomer to explore the energetic consequences of the bound ligand sub-types. With no ligand bound to the LBD, the main energetic contributions come from region III and IV. The Coulomb interaction dominates for region III while both the Coulomb and the Lennard-Jones (LJ) interactions play a dominant role in the recognition of region IV. In the presence of the bound estrogenic ligand DES, the Coulomb interaction between region I and the other LBD monomer reduces significantly. However, the interaction profile of region II remains unaltered. Interestingly, the interactions between region III and the other LBD monomer reduces significantly while regions IV interacts more strongly. For both regions, significant changes were observed in the Columbic interactions. When DES is bound to the LBD, the maximum contribution to the interaction energy comes from region IV [38] . Binding of 4-OHT and/or ICI induces a different pattern in the interaction energy profile. In the presence of 4-OHT in the LBD, the energetic contribution of region I increases while it decreases significantly for region III. Again, the main energetic contribution comes from region IV. In the case of 4-OHT bound to the ERα dimer, the interaction profile of region IV is comparable to the interaction energy profiles of the ligand-free ERα-LBD dimer with a minor reduction in the LJ interaction energy. On the contrary, in the presence of ICI, the interaction energies between the two dimers reduce in general, and again the main interaction energy contribution comes from region IV. For region III, the Coulomb interaction energy increases significantly compared to 4-OHT-bound ERα-LBD dimer.
In accordance with the interaction analysis, it was observed that when 4-OHT and ICI are bound to the LBD, the Cterminal end residues of region I and IV are not involved in the dimer interface. We observed leucine zipper interaction between two monomers involving leucine 508 and 509 from Helix 10 (Fig. S1, supplementary material) . These interactions form the core of the dimer recognition that remains unperturbed in the presence of any bound ligand, whether agonist or SERM, or antagonist. Analysis of the critical residues involved in the dimer interface in the presence of various ligands are summarized in Table 2 . Note that threonine 483, alanine 505, leucine 508, leucine 509, and arginine 515 are necessary and important residues at the dimer interface and that their contributions remain unchanged in the presence of bound agonist/antagonist. Tyrosine 459 acts as a crucial hotspot residue at the dimer interface only when DES or 4-OHT or no ligand is present in the LBD, but it loses contribution as a hotspot residue when pure antagonist ICI is bound to LBD.
Likewise, asparagine 455 and arginine 515 in chain B play a dominant role in dimer recognition in the presence of bound ICI in LBD, but in the presence of bound 4-OHT and DES, these residues lose their contribution to dimer interface recognition.
Principal component analysis
Principal component analysis was carried out to identify most significant structural dynamics from MD trajectories. Massweighted covariance analysis were performed on the MD trajectories and the essential subspace was defined in terms of eigenvalues relative to the corresponding eigenvectors. The first few components were more informative as is evident from their high eigenvalues while the latter components carry very little information about the dimer dynamics (Fig. 5a ). This feature is evident for both ligand-free and ligand-bound ERα-LBD dimers.
As evident from Fig. 5a , in the presence of DES and 4-OHT, the eigenvalue of the first principal component (PC1) is much higher than that of the ligand free or ICI bound ERα-LBD dimer. In all four cases, the first two principal components (PC1 and PC2) together contribute most to the essential Fig. 5b . It is evident from the figure that, in all four cases, PC1 varies more broadly compared to PC2. This corroborates well to the eigenvalue distribution plot where PC1 has the highest eigenvalue (Fig. 5a) . Interestingly, the PC1 vs PC2 representation reveals that, for 4-OHT bound ERα dimer, the 2D projections are much wider compared to the other three cases. This indicates that the 4-OHT-bound ERα-LBD dimer structure accesses more diverse conformational space during the MD simulation.
In silico modelling and analysis of co-repressor binding: implications for tamoxifen resistance An important question is how the agonist and antagonist conformational distributions generated from MD simulations of ERα-LBD dimers in the presence of agonist, antagonist, and SERM ligands can be used to interpret the classical clinical fallacy of "Tamoxifen resistance". It should be noted that selective conformations of 4-OHT-bound ERα dimer generated by the MD simulation are structurally closer to the agonistbound dimer complex but that Helix 12 is still in antagonist position, i.e., bound to the co-activator binding groove. This observation implies that co-activators might not play the decisive role in explaining the resistance phenomenon as their binding surface is occupied by Helix 12. This shifts our focus to co-repressor proteins. However, is should be noted that corepressor proteins are extremely large and are expected to have several contacts with ERα including its DNA binding domain (DBD), as reported by Varlakhanova et al. [39] . Importantly, co-repressor proteins share a binding motif LXXXIXXXL, which is very similar to LXXLL-the common binding motif for activator proteins. Recent structural studies indicate that the LXXXIXXXL motif also binds to the AF2 co-regulator interacting surface of ERα [40] obtained by deleting Helix-12. However, in the agonist-like conformation of 4-OHTbound ERα dimer obtained from our MD simulation, this surface is also blocked by Helix-12. This raises the possibility that the co-repressor might have an alternate binding affinity to the usual Helix 12 binding site formed by Helices 11, 4/5 and 3. In fact, Hu et. al. [41] reported that the CoRNR2 co-activator peptide binds to the usual Helix 12 binding site formed by Helices 11, 4/5 and 3 in agonist-bound RXR protein (retinoid X receptor, another nuclear hormone protein). To explore this unique possible mode of co-repressor binding to the ERα homo-dimer, we further characterized the usual Helix 12 binding pocket or new co-repressor binding pocket framed by Helices 11, 4/5 and 3 for both agonist and antagonist ERα conformations in presence of bound 4-OHT. We refer to this mode of co-repressor recognition as "non-classical" mode. Interestingly, the Q-site-finder-a protein binding pocket finding algorithm-also predicts a possible binding pocket in this non-classical co-repressor binding site.
In the 4-OHT-bound initial antagonist conformation of ERα, the non-classical co-repressor binding site has a volume of 231 Å 3 (Fig. 6 ). It should be noted that, in this conformation, Helix 10 is nearly in continuous with Helix 11 and the linker loop of Helix 11 and 12 extends far enough round to frame the co-repressor binding site. On the other hand, the agonist-like ERα conformations with bound 4-OHT that appeared in the later stages of simulation reveal that Helix 11 is slightly tilted, and that the kink between Helix 10 and Helix 11 is more prominent (Fig. 4a, III) . This tilted position of Helix 11 allows further coiling of the loop regions between Helix 11 and Helix 12. Due to the concomitant movement of Helix 11 and the loop regions joining Helix 11 and Helix 12, the nonclassical co-repressor binding site reduces further to 115 Å 3 . This almost completely precludes the possibility of corepressor binding. Co-repressor peptide binding in this site was performed by RosettaDock program. In 4-OHT-bound ERα antagonist conformation, the peptide binds successfully in this non-classical co-repressor binding site, as is evident from Fig. 7 (deep green) . But docking failed for 4-OHT-bound ERα agonist conformation generated through MD simulation. We aligned the MD average ERα agonist conformation on the co-repressor bound ERα agonist conformation. From Fig. 7b , The loss of the co-repressor recognition in 4-OHT-bound ERα agonist conformation might induce some transcriptional activity of the dimer complex. Nevertheless, this site of corepressor recognition is a low affinity site, since Helix 12 and its linker loop region provide steric constraints to corepressor recognition at this site. Binding of Helix 12 in the co-activator/co-repressor binding site raises the possibility of co-repressor peptide binding at this non-classical site of the LBD and presents the possibility of agonist action by 4-OHTbound ERα, thus explaining "tamoxifen resistance".
Discussion
As formation of the ERα dimer is one of the essential steps that regulates DNA recognition and gene expression in this system, the aim of the present work was to provide detailed structural insight into the effect of the ligand-regulated response on the ERα-LBD dimer using in silico studies. We simulate the ERα-LBD dimer in the presence of a bound agonist (diethylstilbestrol, DES), a SERM (4-hydroxy tamoxifen, 4-OHT), and a pure antagonist (ICI 182,780, ICI) and elucidated the conformational changes and the dimer interface to further understand the ligand-selective response of ERα. ERα was found to have an intrinsic ability to form a stable dimer without any ligand, which is in accordance with kinetic studies that show that unliganded ERα exists as a stable dimer with a slow dissociation rate [42] . The presence of an agonist ligand, DES, in the LBD further stabilizes the dimer, while binding of 4-OHT induces structural fluctuations in the dimer complex but that do not lead to any destabilization of the dimer, which again is in agreement with the solution study [42] . The presence of ICI in the LBD also allows ERα to exist as a dimer complex in an antagonist conformation. For the dimer interface, we found that the essential dimer surface comprises residues 421-437 of Helix 7, residues 448-461 from the C-terminal portion of Helix 8, residues 473-490 from Helix 9, residues 496-523 from Helix 10 and Helix 11; and those remain nearly unchanged with agonist, antagonist or SERM. Residues leucine 508 and 509 are involved in a leucine zipper interaction that forms the core of dimer recognition. Secondary structure analysis of the MD trajectories revealed a distinctive feature: estrogenic ligand DES stabilizes the α-helical structure of the dimer interface region while 4-OHT and ICI induce structural destabilization, particularly on Helix 12. In the presence of 4-OHT at the LBD in the dimer, the α-helical content of those interface regions decrease, with a concomitant increase in turn propensity. However, ICI, a pure antagonist, exhibited a strong ability to disrupt the secondary structure of the interface region and Helix 12. This is consistent with the fact that in the only crystal structure available of rat ERβ LBD with pure antiestrogen ICI 164,384, the longer side chain of ICI 164,384 binds along the co-activator recruitment site. This abolishes the interaction of helix 12 with the LBD such that it is completely disordered. This overall conformation could favor the recruitment of corepressors and resemble the misfolded conformation of ERα, thus promoting degradation of the protein [43] .
Principal component analysis (PCA) and cluster analysis on MD trajectories led to an interesting observation. PCA revealed that, in the essential subspace, 4-OHT-induced ERα conformational dynamics are quite distinct from a pure antagonist-induced structural dynamics. This observation can be used to interpret the observed estrogenic effects of tamoxifen on the endometrium, bone, and cardiovascular system [16] , and also tamoxifen-resistant tumor growth in breast tissues. These observations can be rationalized by attributing the antagonist action of tamoxifen mainly to its effect on Helix 12; this effect is highly dependent on the absolute and relative levels of co-repressor and co-activator proteins expressed in particular tissues. We further studied the possibility of a prototype co-repressor peptide binding in a distinct binding site formed by Helices 11, 4/5 and 3, as depicted in the RAR-RXR heterodimer complex [41] . Our in silico simulation data suggested that recruitment of the proper co-repressor stabilizes the antagonist conformation of the ERα dimer, thus deactivating DNA recognition and gene transcription. However, the absence of co-repressor in the "non-classical" binding cleft shifts the equilibrium of the dimer complex towards the agonist conformation, thus promoting ERα transactivation. These effects might be dominant in bone and endometrium tissues. Tamoxifen resistance in breast tissue can also be rationalized in terms of altered relative expression levels of co-repressor and co-activator proteins. A decreased expression of co-repressor protein can stabilize the agonist conformation of the ERα dimer, paving the way for any tamoxifen-induced ERα trans-activation. From a cellular perspective, tamoxifen resistance represents a complex phenomenon due to the involvement of various co-regulators [24, 44] and their correlated expression profiles together with the involvement of various signalling pathways [20] [21] [22] . Studying ligand-selective structural modulations of these agonist and antagonist conformations of LBD, we were able identify structural differences pertaining to "tamoxifen resistance" which complement the clinical observations regarding the role of co-regulatory proteins [24] . From a therapeutic perspective, the identification of a possible new co-repressor binding site and its role in antagonist to agonist conformational transitions provides an alternate therapeutic strategy to design peptide or peptidomemetic drugs that can be used to overcome resistance to tamoxifen.
